On Nov 15, major Wall Street analysts update their ratings for $Biogen (BIIB.US)$, with price targets ranging from $204 to $300.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $204.
Baird analyst Brian Skorney maintains with a buy rating, and adjusts the target price from $294 to $300.
Raymond James analyst Danielle Brill maintains with a hold rating.
Wolfe Research analyst Alexandria Hammond initiates coverage with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:
The approach taken by the company to counteract the decline of its core franchise involves focusing on the development of assets aimed at addressing significant unmet needs within challenging indications. It has been noted that the company's pipeline appears to carry a higher clinical risk compared to its major biotech contemporaries, yet this also implies substantial potential value.
The firm believes the application for lecanemab in amyloid-positive early Alzheimer's disease has become more favorable for the European Commission's consideration following the decision to exclude APOE4 homozygotes from the treatment group. This move is seen as enhancing the prospects for approval, with a decision anticipated within a two-month time frame.
Here are the latest investment ratings and price targets for $Biogen (BIIB.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
